AA PHARMA MINOCYCLINE CAPSULE 100 MG

APOTEX INC - WESTON ONTARIO - CANADAAPOTEX INC - ETOBICOKE (CANADA)🇸🇬 Health Sciences Authority

Approval Date: Oct 5, 1998
Approval ID: 4814c0eb6c088e18
Company: APOTEX INC - WESTON ONTARIO - CANADAAPOTEX INC - ETOBICOKE (CANADA)
Type: Therapeutic

Approval Details

Approval Id: 4814c0eb6c088e18
Drug Name: AA PHARMA MINOCYCLINE CAPSULE 100 MG
Product Name: AA PHARMA MINOCYCLINE CAPSULE 100 MG
Approval Number: SIN10155P
Approval Date: 1998-10-05
Registrant: PHARMAFORTE SINGAPORE PTE LTD
Licence Holder: PHARMAFORTE SINGAPORE PTE LTD
Drug Type: Therapeutic
Forensic Classification: PRESCRIPTION ONLY MEDICINES
Dosage Form: CAPSULE
Dosage: DOSAGE AND ADMINISTRATION Children 13 Years of Age or Older: The usual dosage of AA PHARMA MINOCYCLINE (minocycline hydrochloride) is 4 mg/kg initially followed by 2 mg/kg every 12 hours. Tetracyclines are not recommended in children under 13 years of age (see Warnings – please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information). Adults: The usual oral dosage of AA PHARMA MINOCYCLINE is 100 mg or 200 mg initially, followed by 100 mg every 12 hours. Alternatively, if more frequent doses are preferred, two or four 50 mg doses may be given initially, followed by one 50 mg dose every 6 hours. Therapy should be continued for 1 or 2 days beyond the time when characteristic symptoms or fever have subsided. For treatment of syphilis, AA PHARMA MINOCYCLINE therapy should be administered over a period of 10 or 15 days. Close follow-up, including laboratory tests, is recommended. Concomitant therapy: Antacids containing aluminum, calcium or magnesium and/or iron preparations impair absorption and should not be given to patients taking minocycline.
Route Of Administration: ORAL
Indication Info: INDICATION AND CLINICAL USES AA PHARMA MINOCYCLINE (minocycline hydrochloride) may be indicated for the treatment of the following infections due to susceptible strains of the designated organisms: Gallbladder infections caused by Escherichia coli; Urinary tract infections: cystitis, gonorrhea, pyelonephritis caused by Escherichia coli, Proteus species, Klebsiella species, Enterobacter aerogens, Neisseria gonorrhoeae. When penicillin is contraindicated, minocycline may be employed as an alternative drug in the treatment of anal and pharyngeal gonorrhea and syphilis. Skin and soft tissue infections: Abscess cellulities, furunculosis, impetigo and pyoderma caused by: Staphylococcus epidermidis, Staphylococcus aureus, Streptococcus pyogenes, Proteus species, Escherichia coli. Although tetracyclines are not the drugs of choice in any staphylococcal or streptococcal infection, minocycline could be useful in circumstances where these organisms are shown to be resistant to other agents but sensitive to minocycline. Bacterial evaluation of clinical cases involving proteus suggests a relatively lower success rate may be expected where these organisms are concerned. Respiratory tract infections: bronchitis, pharyngitis, pneumonia, bronchopneumonia, sinusitis and tonsillitis caused by: Haemophilus Influenzae, Klebsiella species, Enterobacter species. Tetracyclines should not be prescribed for acute throat infections.
Contraindications: CONTRAINDICATIONS History of hypersensitivity to minocycline or any other tetracyclines.
Atc Code: J01AA08
Atc Item Name: minocycline
Pharma Manufacturer Name: PHARMAFORTE SINGAPORE PTE LTD

Active Ingredients

MINOCYCLINE HCl EQV MINOCYCLINE

100 mg

MINOCYCLINE HCL EQV MINOCYCLINE

100 MG

Approved

Quick Info

Agency

HSA

Country

🇸🇬

Approval Date

Oct 5, 1998

Approval ID

4814c0eb6c088e18

Type

Therapeutic

Back to HSA Approvals